Concepedia

Sarah Bakker

SB

Statistics

Publications

11

Citations

623

H-Index

11

Active since

2002

Affiliations

Micropore Technologies (United Kingdom)(Current)

New Zealand Institute for Public Health and Forensic Science

Sarah Bakker is an author at Micropore Technologies (United Kingdom) specializing in infectious diseases, medical microbiology, and microbiology.

ORCID

Publications per year

2002–2024

11

Publications

11

Molecular characterization of macrolide resistance mechanisms among <i>Streptococcus pneumoniae</i> and <i>Streptococcus pyogenes</i> isolated from the PROTEKT 1999-2000 study

David J. Farrell, Ian Morrissey, Sarah Bakker et al. · Journal of Antimicrobial Chemotherapy · 2002 · 155 citations · Full text

, , +16

Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of <i>Streptococcus pneumoniae</i> from the PROTEKT 1999-2000 Study

David J. Farrell, Stephen Douthwaite, Ian Morrissey et al. · Antimicrobial Agents and Chemotherapy · 2003 · 99 citations · Full text

, , +17

Molecular Epidemiology of Multiresistant <i>Streptococcus pneumoniae</i> with Both <i>erm</i> (B)- and <i>mef</i> (A)-Mediated Macrolide Resistance

David J. Farrell, Ian Morrissey, Sarah Bakker et al. · Journal of Clinical Microbiology · 2004 · 85 citations · Full text

, , +17

In Vitro Activities of Telithromycin, Linezolid, and Quinupristin-Dalfopristin against <i>Streptococcus pneumoniae</i> with Macrolide Resistance Due to Ribosomal Mutations

David J. Farrell, Ian Morrissey, Sarah Bakker et al. · Antimicrobial Agents and Chemotherapy · 2004 · 78 citations · Full text

, , +17

Global distribution of TEM-1 and ROB-1 β-lactamases in Haemophilus influenzae

David J. Farrell, Ian Morrissey, Sarah Bakker et al. · Journal of Antimicrobial Chemotherapy · 2005 · 77 citations

, , +17

1–5 of 11